Table 4.

Summary of adverse events.

Adverse event n (%)	PL group (n = 32)		PR group (n = 29)
	Any grade	Grade ≥ 3	Any grade	Grade ≥ 3
Elevated AST level	3 (9.38)	0	4 (13.79)	0
Hyperbilirubinemia	2 (6.25)	0	3 (10.34)	0
Thrombocytopenia	5 (15.63)	0	5 (17.24)	2 (6.90)
Hypertension	12 (37. 5)	2 (6.25)	8 (27.59)	0
Diarrhea	6 (18.75)	0	4 (13.79)	0
Fatigue	8 (25)	0	7 (24.14)	0
Hoarseness	3 (9.38)	0	3 (10.34)	0
Proteinuria	4 (12.5)	2 (6.25)	0	0
Nausea	1 (3.13)	0	0	0
Hand-foot skin reaction	9 (28.13)	1 (3.13)	15 (51.72)	5 (17.24)
RCCEP	4 (12.5)	0	3 (10.34)	1 (3.45)
Rash	2 (6.25)	0	4 (13.79)	0
Hypothyroidism	6 (18.75)	0	7 (24.14)	0
Hyperthyroidism	5 (15.63)	0	4 (13.79)	0
ICIs-Induced hepatitis.	2 (6.25)	0	0	0
ICIs-Induced pneumonia	1 (3.13)	0	0	0

AST, aspartate aminotransferase; RCCEP, reactive cuntaneous capillary endotheial proliferation; ICIs, Immune Checkpoint Inhibitors.